K

Ki Health Partners, LLC | New England Institute for Clinical Research

Research site
(Unclaimed)
Location
30 Buxton Farm Road Suite 230, Stamford, Connecticut, United States of America

Site insights

Top conditions

Top treatments

Galcanezumab
Lasmiditan
LY573144
Erenumab
Atogepant
Irsenontrine
CNP520
ABBV-950
334
LY3202626

Parent organization

This site is a part of Ki Health Partners, LLC

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 36 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling
Migraine
Drug: Erenumab Dose 3
Drug: Erenumab Dose 1

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling
Migraine
Drug: Erenumab Dose 2
Drug: Erenumab Dose 3

Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the tre...

Active, not recruiting
Spasticity
Drug: Phase 2; Low Dose MYOBLOC
Drug: Phase 3; Placebo

Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the tre...

Active, not recruiting
Cerebrovascular Accident
Traumatic Brain Injury
Drug: Phase 3; MYOBLOC
Drug: Phase 2; Placebo

Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tas...

Active, not recruiting
Upper Limb Essential Tremor (UL ET)
Drug: Placebo for BOTOX
Biological: BOTOX

Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint moveme...

Active, not recruiting
Upper Limb Spasticity
Drug: Placebo for ABBV-950
Biological: ABBV-950

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting
Alzheimer's Disease (AD)
Drug: Placebo for ABBV-552
Drug: ABBV-552

Trial sponsors

Lilly logo
Allergan logo
AbbVie logo
Amgen logo
K
Supernus Pharmaceuticals logo
A
A
Eisai logo
Lundbeck logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems